Last reviewed · How we verify
AVA
AVA is an anthrax vaccine that stimulates the immune system to produce antibodies against anthrax toxins, providing protection against infection by Bacillus anthracis.
AVA is an anthrax vaccine that stimulates the immune system to produce antibodies against anthrax toxins, providing protection against infection by Bacillus anthracis. Used for Prevention of anthrax disease in persons at high risk of exposure (occupational, military, or post-exposure prophylaxis).
At a glance
| Generic name | AVA |
|---|---|
| Also known as | Anthrax vaccine adsorbed (BioThrax) |
| Sponsor | Emergent BioSolutions |
| Drug class | Inactivated bacterial vaccine |
| Target | Bacillus anthracis protective antigen (PA) and lethal factor |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
AVA (Anthrax Vaccine Adsorbed) contains inactivated anthrax spores and cell-free filtrate antigen adsorbed to aluminum hydroxide. It works by inducing both humoral and cell-mediated immune responses that generate protective antibodies against protective antigen (PA) and other anthrax virulence factors, preventing disease establishment and progression if exposure occurs.
Approved indications
- Prophylaxis of anthrax infection in persons at high risk of exposure
- Post-exposure prophylaxis following confirmed or suspected anthrax exposure
Common side effects
- Local injection site reactions (erythema, edema, pain)
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Impact of CO2 Absorption on Gas Exchange and Ventilation Patterns While Breathing Into a Snow Air Pocket (NA)
- Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
- Prospective Analysis of Arteriovenous Access (AVA) Use for Continuous Renal Replacement Therapy (CRRT)
- Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
- Comparison of the Ultrasonic Cardiac Output Monitor and Echocardiography for Hemodynamic Assessment in Pediatric Anesthesia
- Post Marketing Clinical Study on the Efficacy of Lenses From a New Prescription Protocol (NA)
- Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study (PHASE2)
- Ciprofloxacin BioThrax Co-Administration Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |